Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Antibe Therapeutics Inc (OP: ATBPF )

N/A UNCHANGED
Last Price Updated: 3:46 PM EDT, Apr 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2156
Today's Range N/A - N/A
52wk Range 0.1113 - 0.8425
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
From Antibe Therapeutics Inc.
Via Business Wire
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
From Antibe Therapeutics Inc.
Via Business Wire

Performance

More News

Read More
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
From Antibe Therapeutics Inc.
Via Business Wire
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
From Antibe Therapeutics Inc.
Via Business Wire
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Reports Q3 2024 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Extends Early Warrant Exercise Incentive Program
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Announces Early Warrant Exercise Incentive Program
From Antibe Therapeutics Inc.
Via Business Wire
OTC Markets Group Announces the 2024 OTCQX Best 50
From OTC Markets
Via GlobeNewswire
Antibe Therapeutics Announces Amendment to Warrant Terms
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Reports Q2 2024 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Announces Results of 2023 Annual Meeting
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Reports Q1 2024 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Reports 2023 Year-End Results and Business Highlights
From Antibe Therapeutics Inc.
Via Business Wire
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit
From Antibe Therapeutics Inc.
Via Business Wire
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Provides April 2023 Corporate Update
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Reports Q3 2023 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Reports Q2 2023 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary
From Antibe Therapeutics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.